Literature DB >> 8321833

Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans.

C V Thanh-Barthet1, M Urtizberea, A E Sabouraud, N J Cano, J M Scherrmann.   

Abstract

Anti-sheep Fab fragment antisera were produced in rabbits using sheep digoxin-specific Fab fragments (Digidot) as immunogen. These antisera were used for the development of a radioimmunoassay (RIA) of sheep Fab fragments in human plasma and urine using 125I-labeled Fab fragments. Interference in the assays by digoxin, human proteins, and antibodies from different species was insignificant, but cross-reactivity between anti-sheep Fab antisera and goat IgG or Fab fragments was 22 to 67%. The limit of detection was 0.1 microgram/mL and the assay was linear over a 0.6-28 micrograms/mL range of Fab fragments. Intra- and interassay coefficients of variation were less than 6.9 and 10.5%, respectively. Accuracy of plasma and urine assays at various Fab fragment levels ranged from 96 to 106%. RIA was applied to the pharmacokinetic study of sheep digoxin-specific Fab fragments in one patient acutely intoxicated by digitoxin and treated with Digidot. The Fab elimination half-life was 12.1 hr. Steady-state volume of distribution and total-body clearance were 10.8 L and 23.4 mL/min, respectively. Unchanged Fab fragments (50 kD) and degradation products (25 kD) isolated by gel filtration chromatography of a urine sample cross-reacted with the anti-Fab antiserum.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321833     DOI: 10.1023/a:1018903614997

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Pharmacokinetics of total and free digoxin and Fab fragments in 5 intoxicated patients after administration of specific anti-digoxin Fab fragments.

Authors:  M Urtizberea; A Sabouraud; M Lachaise; O Chappey; V Cosson; F J Baud; J M Scherrmann
Journal:  Arch Toxicol Suppl       Date:  1991

Review 2.  Validation of bioanalytical methods.

Authors:  H T Karnes; G Shiu; V P Shah
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

3.  Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication.

Authors:  W Schaumann; B Kaufmann; P Neubert; A Smolarz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay.

Authors:  R Müller
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

5.  Colchicine-specific Fab fragments alter colchicine disposition in rabbits.

Authors:  A E Sabouraud; M Urtizberea; N J Cano; M Grandgeorge; J M Rouzioux; J M Scherrmann
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

6.  The use of an enzyme-linked immunosorbent assay to study the disposition of sheep digoxin-specific immunoglobulin G and Fab fragments in the rat.

Authors:  P C Johnston; I H Stevenson; D S Hewick
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

7.  The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit.

Authors:  M P Timsina; D S Hewick
Journal:  J Pharm Pharmacol       Date:  1990-08       Impact factor: 3.765

8.  Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments.

Authors:  A Sabouraud; M Urtizberea; M Grandgeorge; P Gattel; M E Makula; J M Scherrmann
Journal:  Toxicology       Date:  1991       Impact factor: 4.221

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity.

Authors:  J A Mauskopf; T L Wenger
Journal:  Am J Cardiol       Date:  1991-12-15       Impact factor: 2.778

View more
  3 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.

Authors:  José María Gutiérrez; Guillermo León; Bruno Lomonte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Fab antibody fragments: some applications in clinical toxicology.

Authors:  Robert J Flanagan; Alison L Jones
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 3.  Estimating xenobiotic half-lives in humans from rat data: influence of log P.

Authors:  J G Sarver; D White; P Erhardt; K Bachmann
Journal:  Environ Health Perspect       Date:  1997-11       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.